Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CET

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
12:31p ASTRAZENECA : provide insight into biomarkers and personalised treatment at Asth..
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/09 ASTRAZENECA : Bevespi Aerosphere Now Available in US for COPD
01/05 WuXi AppTec Spins Off Subsidiary for HK Listing
01/04 ASTRAZENECA : *rpt/jpmorgan cuts astrazeneca price target to 4300 pence - 'neutr..
01/04 ASTRAZENECA : Joins ACRP Workforce Development Steering Committee Defining Compe..
01/03 ASTRAZENECA : *jpmorgan cuts astrazeneca price target to 4300 pence - 'neutral'
01/03 ASTRAZENECA : NCI - Early-phase trial demonstrates shrinkage in pediatric neural..
01/03 Credit Suisse, AstraZeneca among top BofA-ML's top European picks for first q..
More news
Sector news : Pharmaceuticals - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/13 Adding AstraZeneca To Our Model Portfolio
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 Merck gets upgrades on leadership in drug/chemo combo race
01/11 Why Regeneron May Have Lots Of Growth Ahead
Advertisement
Financials ($)
Sales 2016 22 665 M
EBIT 2016 6 325 M
Net income 2016 2 497 M
Debt 2016 11 353 M
Yield 2016 4,95%
P/E ratio 2016 27,48
P/E ratio 2017 27,27
EV / Sales 2016 3,63x
EV / Sales 2017 3,85x
Capitalization 71 003 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 64,4 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.86%70 916
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%204 641
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%189 749
MERCK & CO., INC.5.89%171 880
More Results